1Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J]. Hypertension,2008, 51(6) : 1403-1419.
2Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J]. Circulation,2009,119(3) :480-486.
3Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data [J].Lancet, 2005, 365 (9455) :217-223.
4Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study[J].Lancet, 2009, 373 (9671) : 1275-1281.
5Jordan J. Sympathetic genes, baroreflexes and hypertension[J]. Clin Auton Res, 2004,14(6) : 358-359.
6Smith PA, Graham LN, Mackintosh AF, et al. Relationship between central sympathetic activity and stages of human hypertension[J]. Am J Hypertens,2004,17(3) :217 -222.
7Benjelloun H, Aboudrar S, Jroundi I, et al. Sympathetic response in primary hypertension[J]. Ann Cardiol Angeiol (Paris),2009,58 (3) :139-143.
8Hausberg M, Koseh M, HarmeIink P, et al. Sympathetic nerve activity in end-stage renal disease[J]. Circulation, 2002,106 (15) 1974-1979.
9Hendel MD, Collister JP. Renal denervation attenuates long-term hypertensive effects of Angiotensin Ⅱ in the rat[J]. Clin Exp Pharmacol Physiol, 2006,33(12) : 1225-1230.
10Alexander BT, Hendon AE, Ferril G, et al. Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion[J]. Hypertension, 2005,45 (4) :754-758.
2Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American heart association professional education committee of the council for high blood pressure research[J]. Circulation,2008, 117(25):e510-e526.
3Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American heart association[J]. Circulation,2010,121(7) : e46-e215.
4Krum H, Schlaich M, Sobotka P, etal. Novel procedureand device-based strategies in the management of systemic hypertension [J]. Eur Heart J,2011,32(5):537-544.
5Lohmeier TE, Dwyer TM, Irwin ED, et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension[J]. Hypertension,2007,49(6) : 1307-1314.
6Lohmeier TE, Dwyer TM, Hildebrandt DA, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension[J]. Hypertension, 2005,46 (5) : 1194-1200.
7Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase Ⅱ Rheos feasibility trial[J]. J Vase Surg,2006,44(6), 1213-1218.
8Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension results from the double-blind, randomized, placebo-controlled rheos pivotal trial[J]. J Am Coil Cardiol, 2011,58 (7) : 765-773.
9Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study[J ]. J Am Coll Cardiol, 2010,56 ( 15 ) : 1254-1258.
10DiBona GF, Kopp UC. Neural control of renal function[J]. Physiol Rev,1997,77(1) :75-197.
